Skip to main content
Premium Trial:

Request an Annual Quote

RxP and BioTrove Ink SNP, Gene-Expression Deal

NEW YORK, Jan. 30 (GenomeWeb News) - BioTrove and RxGen PrimaTox are working jointly to provide gene expression and SNP assays for primates and humans, BioTrove said today.

Under the deal, RxP will provide its tox-optimum assays exclusively to BioTrove, either as stand-alone products or as a service. BioTrove will manufacture the assays to RxP's specifications, using its OpenArray platform.

Financial details were not disclosed.

As GenomeWeb News reported last week, RxGen PrimaTox is a wholly owned subsidiary of RxGen focused on drug-safety products and services. It is also building a primate-based molecular toxicology database to be available on a subscription basis.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.